New faecal tests for colorectal cancer screening: Is tumour pyruvate kinase M2 one of the options? [1]

British Journal of Cancer

Volumn 97, Issue 11, 2007, Pages 1595-1596

  Shastri, Y M ^a   Stein, J M ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER SCREENING; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL TUMOR; DIAGNOSTIC ACCURACY; FECES ANALYSIS; HUMAN; LETTER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

COLORECTAL NEOPLASMS; FECES; HUMANS; MASS SCREENING; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 36448996678     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604039     Document Type: Letter

References (10)

1. Allison JE, Tekawa IS, Ransom LJ, Adrain AL (1996) A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 334: 155-159
2. Anderson JC, Attam R, Alpern Z, Messina CR, Hubbard P, Grimson R, Ells PF, Brand DL (2003) Prevalence of colorectal neoplasia in smokers. Am J Gastroenterol 98: 2777-2783
3. Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H (2007) Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer 98: 1329-1334
4. Hoepffner N, Shastri YM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein J (2006) Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study 1. Aliment Pharmacol Ther 23: 145-154
5. Koss K, Maxton D, Jankowski JA (2005) The Potential Use of Fecal Dimeric M2 Pyruvate Kinase (tumor M2-Pk) in Screening for Colorectal Cancer. Gastroenterology 128: A-642
6. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y (2005) A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129: 422-428
7. Shastri YM, Naumann M, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein JM (2006) Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer 119: 2651-2656
8. Shastri YM, Povse N, Hoepffner N, Loitsch S, Caspary WF, Schrjder O, Stein J (2007) Prospective evaluation of fecal tumor Pyruvate Kinase type M2 (M2-PK) with a rapid bedside immunological test for screening of Colorectal neoplasia. Gastroenterology 132(4) (Suppl 1): A-30
9. Shastri YM, Stein J (2007) Fecal M2-PK, not a specific biomarker for Colorectal cancer screening. World J Gastroenterol 13: 2768-2769
10. Smith A, Young GP, Cole SR, Bampton P (2006) Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 107: 2152-2159